Vivos Therapeutics Inc. (VVOS) shares took a significant dive on Thursday, plummeting 26.1% to $3.05. The downturn was triggered by the company’s announcement of a $4.3 million registered offering of 1.36 million shares of common stock at $3.15 per share. This direct offering, slated to close on September 20, is anticipated to generate approximately $4.3 million in gross proceeds, which Vivos plans to utilize for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The news comes on the heels of discussions surrounding the investment potential of VVOS. Investors often consider a company’s capital allocation strategies when deciding whether a stock is worth buying. These strategies involve how companies distribute profits to shareholders, either through dividends or by repurchasing their own stock (buyback programs). While Vivos Therapeutics does not currently pay dividends, the company has other avenues to return value to its shareholders.
For investors seeking dividend-paying companies, Benzinga’s dividend calendar provides a valuable resource. This calendar lists companies that are scheduled to pay dividends, allowing investors to determine the potential yield they could earn by holding shares. For instance, if you’re aiming for an annualized return of 23.1%, you could purchase a share of North American Finl 15 before September 30, 2024. This would entitle you to a nominal payout of $0.11 on October 10, 2024.
Buyback programs, on the other hand, offer a different approach to shareholder value. Companies can authorize buyback programs and repurchase their shares at their discretion over time. These programs often serve as a support for share prices by creating a backstop for demand. To gauge whether Vivos Therapeutics has recently authorized a buyback program, you can refer to the latest news updates related to the company.
According to data from Benzinga Pro, VVOS has a 52-week high of $48.79 and a 52-week low of $1.91. While the recent stock offering may have contributed to the current price decline, investors will be watching closely to see how Vivos utilizes the newly acquired funds and whether this will impact their future investment decisions.
